A deeper understanding of the mechanisms regulating tissue fibrosis, along with targeted strategies to inhibit Gal‐3 in the liver, provides a compelling rationale for developing novel therapeutic approaches for patients suffering from liver fibrosis. The gene discussed is LGALS3; the disease is Hepatic fibrosis.